{"topic":{"0":"RespireRx","1":"RespireRx","2":"RespireRx","3":"RespireRx","4":"RespireRx","5":"RespireRx","6":"RespireRx","7":"RespireRx","8":"RespireRx","9":"RespireRx","10":"RespireRx","11":"RespireRx","12":"RespireRx"},"dialog_lvl":{"0":"model","1":"model","2":"model","3":"model","4":"model","5":"model","6":"model","7":"model","8":"model","9":"model","10":"model","11":"model","12":"model"},"role":{"0":"Explainer","1":"Explainee","2":"Explainer","3":"Explainee","4":"Explainer","5":"Explainee","6":"Explainer","7":"Explainee","8":"Explainer","9":"Explainee","10":"Explainer","11":"Explainee","12":"Explainer"},"turn_num_tokens":{"0":12,"1":9,"2":31,"3":9,"4":45,"5":8,"6":15,"7":8,"8":21,"9":7,"10":66,"11":6,"12":21},"turn":{"0":"Hi, I'm your automated assistant. I can answer your questions about RespireRx.","1":"What is the difference between RespireRx and Cortex Pharmaceuticals?","2":"RespireRx RespireRx Pharmaceuticals Inc. (formerly Cortex Pharmaceuticals, Inc.) () is a pharmaceutical company based in Glen Rock, New Jersey specializing in positive allosteric modulators of the AMPA receptor known as Ampakines.","3":"Are there any other interesting aspects about this article?","4":"February 2005 \u2013 Cortex received U.S. Food and Drug Administration approval to begin Phase II clinical trials for CX717 for use as a treatment for Alzheimer\u2019s, ADHD and Sleep disorders.2006 \u2013 The FDA halted clinical trials for CX717 because they feared the drug was toxic.","5":"Did the drug ever pass the FDA approval?","6":"They later allowed testing to continue but at doses too low to have any effect.","7":"Is there anything else noteable about the company?","8":"July 2007 \u2013 The FDA gave Cortex permission to continue with clinical trials for CX717, as a treatment for Alzheimer's disease.","9":"What other clinical trials were being done?","10":"September 2007 \u2013 Cortex filed with the FDA to test CX717 as a treatment for ADHD.October 2007 \u2013 Dr. Pierre Tran became Chief Medical Officer at Cortex after the FDA refused to let the company proceed with Phase II clinical trials for CX717 as a treatment for ADHD.March 2008 \u2013 German regulators approved clinical studies for using CX717 to prevent breathing problems caused by opiate pain-killers.","11":"Did anyone else join the company?","12":"May 2008 \u2013 President and CEO Dr. Roger Stoll announced that he was resigning and would be replaced by Mark Varney."}}